Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $95M | $24M | $23M | $43M | 11.7% | -31.8% | -60.7% |
| 2024 | $139M | $71M | $59M | $49M | 27.4% | -0.9% | -13.0% |
| 2023 | $140M | $84M | $68M | $95M | 34.6% | 26.3% | 100.8% |
| 2022 | $111M | $43M | $34M | $42M | 19.9% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 94.57 |
| Operating Revenue | 94.57 |
| Cost Of Revenue | 29.70 |
| Gross Profit | 64.87 |
| Operating Expense | 41.17 |
| Research And Development | 19.96 |
| Selling General And Administration | 21.21 |
| Total Expenses | 70.87 |
| Operating Income | 23.70 |
| Total Operating Income As Reported | 23.70 |
| EBITDA | 24.26 |
| Normalized EBITDA | 24.26 |
| EBIT | 23.70 |
| Interest Expense | - |
| Net Interest Income | - |
| Other Non Operating Income Expenses | 6.68 |
| Other Income Expense | 6.68 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | - |
| Pretax Income | 30.38 |
| Tax Provision | 7.10 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | 23.28 |
| Net Income From Continuing And Discontinued Operation | 23.28 |
| Net Income From Continuing Operation Net Minority Interest | 23.28 |
| Net Income | 23.28 |
| Net Income Common Stockholders | 23.28 |
| Net Income Including Noncontrolling Interests | 23.28 |
| Normalized Income | 23.28 |
| Diluted NI Availto Com Stockholders | 23.28 |
| Basic Average Shares | 71.53 |
| Diluted Average Shares | 71.87 |
| Reconciled Depreciation | 0.56 |
| Reconciled Cost Of Revenue | 29.70 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Special Income Charges | - |
| Gain On Sale Of Security | - |
| Other Operating Expenses | - |
| Average Dilution Earnings | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| SIGA Technologies, Inc.this co. | SIGA | $318M | 13.65 | 1.60 | 11.7% | 6.73 |
| Abeona Therapeutics Inc. | ABEO | $332M | 4.66 | 2.08 | 44.7% | 3.54 |
| Humacyte, Inc. | HUMA | $331M | -8.10 | 106.40 | -1313.4% | -15.52 |
| Organogenesis Holdings Inc. | ORGO | $319M | 8.62 | 1.06 | 12.3% | 3.71 |
| Rocket Pharmaceuticals, Inc. | RCKT | $319M |
| - |
| - |
| - |
| - |
| - |
| - |
| -1.43 |
| 1.15 |
| -80.5% |
| -1.27 |
| Fennec Pharmaceuticals Inc. | FENC | $318M | -32.67 | 8.97 | -27.5% | -37.76 |
| DiaMedica Therapeutics Inc. | DMAC | $315M | - | 5.61 | -58.4% | - |
| Electromed, Inc. | ELMD | $304M | 40.34 | 7.04 | 17.4% | 26.66 |
| Carlsmed, Inc. | CARL | $303M | -10.22 | 3.06 | -30.0% | -8.40 |
| Peer Median | - | -1.43 | 4.34 | -28.7% | -1.27 | |